Skip to main content
Journal cover image

Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.

Publication ,  Journal Article
Nilsson, MI; Samjoo, IA; Hettinga, BP; Koeberl, DD; Zhang, H; Hawke, TJ; Nissar, AA; Ali, T; Brandt, L; Ansari, MU; Hazari, H; Patel, N ...
Published in: Mol Genet Metab
November 2012

BACKGROUND: Aerobic exercise may be used in conjunction with enzyme replacement therapy (ERT) to attenuate cardiovascular deconditioning, skeletal muscle wasting, and loss of motor function in Pompe disease (glycogen storage disease type II; GSDII), but the effects on lysosomal glycogen content and macroautophagy have not been defined to date. PURPOSE: The main objectives of this study were to determine if acute aerobic exercise enhances 24-h uptake of recombinant human enzyme (rhGAA; Myozyme® [aim 1]) and if endurance training improves disease pathology when combined with ERT [aim 2] in Pompe mice. METHODS: For the first aim in our study, Pompe mutant mice (6(neo)/6(neo)) were grouped into ERT (Myozyme® injection only [40 mg/kg]) and ERT+EX (Myozyme® injection followed by 90 min treadmill exercise) cohorts, and enzyme uptake was assessed in the heart and quadriceps 24h post injection. For the second aim of our study, mutant mice were randomized into control, endurance-trained, enzyme-treated, or combination therapy groups. Exercised animals underwent 14 weeks of progressive treadmill training with or without biweekly Myozyme® injections (40 mg/kg) and tissues were harvested 1 week post last treatment. RESULTS: Myozyme® uptake (GAA activity) was not improved in ERT+EX over ERT alone at 24-h post injection. Endurance exercise training, with or without ERT, improved aerobic capacity and normalized grip strength, motor function, and lean mass (P<0.05), but did not reduce glycogen content or normalize macroautophagy beyond traditional enzyme replacement therapy. CONCLUSIONS: Endurance training is beneficial as an adjunctive therapy to ERT in Pompe disease, although it works by mechanisms independent of a reduction in glycogen content.

Duke Scholars

Published In

Mol Genet Metab

DOI

EISSN

1096-7206

Publication Date

November 2012

Volume

107

Issue

3

Start / End Page

469 / 479

Location

United States

Related Subject Headings

  • alpha-Glucosidases
  • Physical Conditioning, Animal
  • Muscle, Skeletal
  • Mice, Transgenic
  • Mice
  • Male
  • Infusions, Intravenous
  • Humans
  • Heart
  • Glycogen Storage Disease Type II
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nilsson, M. I., Samjoo, I. A., Hettinga, B. P., Koeberl, D. D., Zhang, H., Hawke, T. J., … Tarnopolsky, M. A. (2012). Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab, 107(3), 469–479. https://doi.org/10.1016/j.ymgme.2012.09.010
Nilsson, Mats I., Imtiaz A. Samjoo, Bart P. Hettinga, Dwight D. Koeberl, Haoyue Zhang, Thomas J. Hawke, Aliyah A. Nissar, et al. “Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.Mol Genet Metab 107, no. 3 (November 2012): 469–79. https://doi.org/10.1016/j.ymgme.2012.09.010.
Nilsson MI, Samjoo IA, Hettinga BP, Koeberl DD, Zhang H, Hawke TJ, et al. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab. 2012 Nov;107(3):469–79.
Nilsson, Mats I., et al. “Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.Mol Genet Metab, vol. 107, no. 3, Nov. 2012, pp. 469–79. Pubmed, doi:10.1016/j.ymgme.2012.09.010.
Nilsson MI, Samjoo IA, Hettinga BP, Koeberl DD, Zhang H, Hawke TJ, Nissar AA, Ali T, Brandt L, Ansari MU, Hazari H, Patel N, Amon J, Tarnopolsky MA. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab. 2012 Nov;107(3):469–479.
Journal cover image

Published In

Mol Genet Metab

DOI

EISSN

1096-7206

Publication Date

November 2012

Volume

107

Issue

3

Start / End Page

469 / 479

Location

United States

Related Subject Headings

  • alpha-Glucosidases
  • Physical Conditioning, Animal
  • Muscle, Skeletal
  • Mice, Transgenic
  • Mice
  • Male
  • Infusions, Intravenous
  • Humans
  • Heart
  • Glycogen Storage Disease Type II